ライフサイエンスコーパス: ischemic stroke

1 infarction, coronary revascularization, and ischemic stroke).

2 r vascular events (major coronary events and ischemic stroke).

3 (fibroblast growth factor receptor 1) after ischemic stroke.

4 d thus a potential pharmacological target in ischemic stroke.

5 represent up to two-thirds of cases of acute ischemic stroke.

6 ical substance that affects the prognosis of ischemic stroke.

7 CI, 0.07-0.79) were associated with reduced ischemic stroke.

8 entially useful in the treatment of pain and ischemic stroke.

9 injury in permanent and transient models of ischemic stroke.

10 ay enable the discovery of new therapies for ischemic stroke.

11 iR-15a/16-1 suppresses BBB pathologies after ischemic stroke.

12 the state of the art of management of acute ischemic stroke.

13 ed Cox proportional hazard models for MI and ischemic stroke.

14 art failure, neurodegenerative diseases, and ischemic stroke.

15 sensorimotor and cognitive recovery against ischemic stroke.

16 ue health, and functional recovery following ischemic stroke.

17 1, 2014 with 2-year follow-up after arterial ischemic stroke.

18 = 0.004) were independently associated with ischemic stroke.

19 The clinical end point was ischemic stroke.

20 functionalized polymersomes in experimental ischemic stroke.

21 Multiple risk factors are associated with ischemic stroke.

22 therapeutic target for neuroinflammation and ischemic stroke.

23 death, spontaneous myocardial infarction, or ischemic stroke.

24 n periodontal disease and multiple causes of ischemic stroke.

25 s a potential target to treat acute cerebral ischemic stroke.

26 oring (C statistics, 0.78-0.81; P=0.006) for ischemic stroke.

27 eutrophils to exacerbate brain injury during ischemic stroke.

28 outcomes in stroke mimics versus those with ischemic stroke.

29 69 was involved in brain damage following an ischemic stroke.

30 of classical VKAs, with a better profile for ischemic stroke.

31 ember 2016 for patients aged >=18 years with ischemic stroke.

32 high-risk transient ischemic attack or minor ischemic stroke.

33 y increased VWF and worse brain damage after ischemic stroke.

34 holesterol concentrations had higher risk of ischemic stroke.

35 on plays a key role in neuronal injury after ischemic stroke.

36 elination of hippocampal area after cerebral ischemic stroke.

37 y and protected mice from brain damage after ischemic stroke.

38 apid and accurate diagnosis and treatment of ischemic stroke.

39 NT3 can improve sensorimotor function after ischemic stroke.

40 in neurons and attenuated brain damage after ischemic stroke.

41 nd safe drugs are warranted for treatment of ischemic stroke.

42 old standard for penumbra detection in acute ischemic stroke.

43 ring which time 2,488 were diagnosed with an ischemic stroke.

44 function when delivered after hemorrhagic or ischemic stroke.

45 and cerebral thrombosis, a prerequisite for ischemic stroke.

46 es, such as venous thromboembolism (VTE) and ischemic stroke.

47 of major AF risk factors and higher risk of ischemic stroke.

48 nonsignificant, of myocardial infarction and ischemic stroke.

49 m GRS was a strong, independent predictor of ischemic stroke.

50 nd the predominant cause of heart attack and ischemic stroke.

51 cer cells, and increased brain damage during ischemic stroke.

52 ebral blood flow (CBF) restoration following ischemic stroke.

53 en in 68 (3.5%) of 1,931 patients with acute ischemic stroke.

54 tic strategy to limit brain damage following ischemic stroke.

55 s but poorly understood consequence of acute ischemic stroke.

56 ive effects of lipids and apolipoproteins on ischemic stroke.

57 tiation of pain and neuronal death following ischemic stroke.

58 ribute to the development and progression of ischemic stroke.

59 morrhagic stroke was significantly less than ischemic stroke (0.17 per 100 patient-years in CAP and 0

60 ial infarction, 0.94 (95% CI, 0.75-1.18) for ischemic stroke, 0.92 (95% CI, 0.75-1.12) for major blee

61 ajor coronary events (1.64 [1.35, 2.00]) and ischemic stroke (1.87 [1.73, 2.01]).

62 %), with a low incidence of seizures (1.1%), ischemic stroke (1.9%), intracranial hemorrhage (3.5%),

63 mplications occurred in 4 patients (0.3%): 2 ischemic strokes, 1 transient ischemic attack without re

64 oreal membrane oxygenation patients had more ischemic stroke (10% vs 1%; p < 0.001), hypoxic-ischemic

65 However, ischemic stroke (10% vs 1%; p < 0.001), hypoxic-ischemic

66 .1%); while myocardial infarction (5.2%) and ischemic stroke (3.2%) were uncommon.

67 chemic brain injury, 6% (95% CI, 0.02-0.11%) ischemic stroke, 6% (95% CI, 0.01-0.16%) seizures, and 4

68 hether patients had an eventual diagnosis of ischemic stroke (89/146) or stroke mimic (57/146 SaO pat

69 5% CI: 0.54, 1.23; P-trend = 0.32), 0.84 for ischemic stroke (95% CI: 0.53, 1.34; P-trend = 0.44), an

70 = 29-91%) increase in risk for small vessel ischemic stroke, a 197% increase (95% CI = 59-457%) in r

71 val [CI] = 44-113%) in risk for large artery ischemic stroke, a 57% (95% CI = 29-91%) increase in ris

72 Among patients with large vessel occlusion ischemic stroke, a dose of 0.40 mg/kg, compared with 0.2

73 odel was used to calculate hazard ratios for ischemic stroke across genetic risk groups, adjusted for

74 sociated with the combined outcome of MI and ischemic stroke, adjusted for cardiometabolic risk facto

75 ) could identify subjects at higher risk for ischemic stroke after accounting for traditional clinica

76 CD (cluster of differentiation)-84 in acute ischemic stroke after recanalization and to dissect the

77 we assessed CA status of patients with acute ischemic stroke (AIS) during intravenous r-tPA therapy a

78 he substantial clinical improvement in acute ischemic stroke (AIS) patients treated with mechanical t

79 Ischemic stroke also results in an increase in EcoHIV pr

80 P=0.009) both had increased odds ratios for ischemic stroke, although these two variants were below

81 dose-response pattern with a higher risk of ischemic stroke among individuals in the upper quartiles

82 oxygenation patients, 401 (3.9%) experienced ischemic stroke and 229 (2.2%) experienced hemorrhagic s

83 ts was high with 30 days mortality of 31% in ischemic stroke and 42% in intracerebral hemorrhage.

84 In patients with ischemic stroke and atherosclerosis, an LDL-C target of

85 included consecutive patients admitted with ischemic stroke and atrial fibrillation.

86 ase 3 trials of medical treatments for acute ischemic stroke and corresponding early clinical and exp

87 ortality was 56%, but rates were higher when ischemic stroke and hemorrhagic stroke were present (76%

88 duced sleep slow waves in an animal model of ischemic stroke and identify sleep as a window for posts

89 nger term, the survival curve gradient among ischemic stroke and intracerebral hemorrhage patients st

90 potential causal association of smoking with ischemic stroke and intracerebral hemorrhage using summa

91 me after ICU admission in patients with both ischemic stroke and intracerebral hemorrhage, especially

92 ial atherosclerosis is an important cause of ischemic stroke and is associated with several vascular

93 Summary-level data for ischemic stroke and its subtypes were obtained from the

94 aster thrombolytic treatment times for acute ischemic stroke and modestly lower 1-year all-cause and

95 The associations of HDL-C and HDL-P with ischemic stroke and myocardial infarction (MI) among wom

96 a composite of CVEs including fatal/nonfatal ischemic stroke and myocardial infarction, and cardiovas

97 2014 to describe patients with a nonlacunar ischemic stroke and no convincing etiology.

98 ificantly increases the risk of both primary ischemic stroke and subsequent cardiovascular events.

99 oral anticoagulant initiation after a recent ischemic stroke and the benefit:harm ratio of non-vitami

100 Secondary outcomes were first subsequent ischemic stroke and the incidence of disability within 3

101 n of IDO1 with ischemic heart disease (IHD), ischemic stroke and their risk factors, all-cancer, canc

102 posite of MACE (cardiovascular death, MI, or ischemic stroke) and the composite of cardiovascular dea

103 ts, 1.1% (95% CI = 0.8-1.3%, I(2) = 85%) for ischemic stroke, and 0.2% (95% CI = 0.1-0.3%, I(2) = 64%

104 major coronary events, 1.65 [1.50, 1.80] for ischemic stroke, and 1.35 [1.13, 1.61] for hemorrhagic s

105 ,046 (1.9%) were stroke patients, 4,072 with ischemic stroke, and 2,974 with intracerebral hemorrhage

106 brillation (AF) is associated with a risk of ischemic stroke, and functional myocardial imaging has o

107 ulating MCP-1 levels and risk of any stroke, ischemic stroke, and hemorrhagic stroke during a mean fo

108 ded 3-component MACE (myocardial infarction, ischemic stroke, and mortality) and the 6 individual com

109 s to be associated with an increased risk of ischemic stroke, and potentially cryptogenic stroke in p

110 plications, including myocardial infarction, ischemic stroke, and pulmonary embolism, represent an im

111 site of ASCVD events (myocardial infarction, ischemic stroke, and revascularization with coronary art

112 potentially mono- or oligogenic variants for ischemic stroke, and second, we considered that more com

113 ductions in rates of coronary heart disease, ischemic stroke, and total cardiovascular disease.

114 emergency interventional treatment of acute ischemic stroke, and treatment in dedicated stroke cente

115 a doubled risk of coronary heart disease and ischemic stroke, and worsened heart failure outcomes ind

116 ogic complications: intracranial hemorrhage, ischemic stroke, and/or brain death, as a composite outc

117 tal ischemic heart disease), 8849 and 10,922 ischemic strokes, and 2492 and 2363 hemorrhagic strokes

118 diovascular death, myocardial infarction, or ischemic stroke, as well as cardiovascular death and all

119 intravenous thrombolytic treatment for acute ischemic stroke at 1490 Get With The Guidelines-Stroke h

120 rol efflux capacity) in patients after acute ischemic stroke at 2 time points (24 hours, 35 patients;

121 The predictive outcome was ischemic stroke at 90-day.

122 (CHD; myocardial infarction and fatal CHD), ischemic stroke, atherosclerotic CVD (CHD and stroke), h

123 gly associated with coronary artery disease, ischemic stroke, atrial fibrillation, type 2 diabetes, s

124 ard of care in patients with acute disabling ischemic stroke attributable to large-vessel occlusion a

125 ied a cohort of 19 children who had an overt ischemic stroke before 4 years of age.

126 he assumed multifactorial mechanisms include ischemic stroke, both apparent and silent, cerebral micr

127 tion in preclinical and clinical studies for ischemic stroke, but the influences of S1PR modulation o

128 d male mice (18-20 months) were subjected to ischemic stroke by middle cerebral artery occlusion.

129 inflammatory response and protected against ischemic stroke by regulating the AIM2 inflammasome.

130 Acute ischemic stroke care provides a useful application to de

131 age using summary statistics data for 34,217 ischemic stroke cases and 404,630 noncases, and 1,545 ca

132 consortium with 514,791 individuals (60,341 ischemic stroke cases, and 454,450 non-cases).

133 r-to-needle time reductions (5057 more acute ischemic stroke cases/y in the 0-3-hour window) incentiv

134 usion prior to endovascular thrombectomy for ischemic stroke compared with alteplase.

135 low-up period of up to 3 years were lower in ischemic stroke compared with sepsis (adjusted hazard ra

136 A types in patient blood sequenced 2 d after ischemic stroke, comprising massive decreases of microRN

137 n is a leading risk factor for dementia, how ischemic stroke contributes to this neurodegenerative co

138 Secondary outcomes included any stroke, ischemic stroke, coronary revascularization, cardiovascu

139 of acidotoxicity and in vivo mouse model of ischemic stroke, demonstrating the therapeutic potential

140 We analyzed 1,986 patients with acute ischemic stroke due to anterior circulation large vessel

141 Adult patients (N = 300) with ischemic stroke due to occlusion of the intracranial int

142 and SRs to be independent prognosticators of ischemic stroke during a median follow-up of 37.6 months

143 The Endovascular Treatment in Ischemic Stroke (ETIS) registry is an ongoing, prospecti

144 as been a cornerstone for treatment of acute ischemic stroke for more than 20 years; however, its use

145 angiography examinations for suspected acute ischemic stroke from February 2017 to June 2018.

146 as no effect modification by sex, history of ischemic stroke, glycated hemoglobin A(1c), body mass in

147 cular treatment (EVT) in patients with acute ischemic stroke has an effect on the functional outcome

148 f fatal or nonfatal acute coronary syndrome, ischemic stroke, heart failure, and atrial fibrillation

149 f the study outcomes (myocardial infarction, ischemic stroke, heart failure, and cardiovascular morta

150 r the study outcomes (myocardial infarction, ischemic stroke, heart failure, and cardiovascular morta

151 outcomes including death, all-cause stroke, ischemic stroke, hemorrhagic stroke, and bleeding hospit

152 nd chronic neurological disorders, including ischemic stroke, hemorrhagic stroke, traumatic brain inj

153 ly existing strategy for patients with acute ischemic stroke, however it causes further brain damage

154 The hazard ratios were elevated for ischemic stroke (HR = 1.58, 95% CI: 0.85, 2.93) and hear

155 ny stroke (HR, 0.72 [95% CI, 0.57-0.91]) and ischemic stroke (HR, 0.73 [95% CI, 0.57-0.93]) without i

156 een baseline MCP-1 levels and higher risk of ischemic stroke (HR, 1.11 [1.02-1.21]) but not hemorrhag

157 hazard ratio [HR], 2.20; 95% CI, 1.64-2.95), ischemic stroke (HR, 2.99; 95% CI, 2.01-4.46), atheroscl

158 A) deformations and its prognostic values of ischemic stroke in a large-scale AF population.

159 nt a case of focal cerebral arteriopathy and ischemic stroke in a pediatric patient with coronavirus

160 gent revascularization, and noncardioembolic ischemic stroke in a time to event analysis.

161 Gepants worsened ischemic stroke in mice via collateral dysfunction.

162 d flow in residual peri-infarct cortex after ischemic stroke in mice.

163 e and on brain recovery and plasticity after ischemic stroke in mice.

164 an intermittent risk factor of bleeding and ischemic stroke in patients with AF.

165 ctive deletion of Tak1 also protects against ischemic stroke in prolonged obesity.

166 We conclude that RIC in the setting of acute ischemic stroke in rats is safe, reduces infarct size an

167 conventional echocardiographic measures for ischemic stroke in the AF population but not incremental

168 ations are associated with increased risk of ischemic stroke in the general population.

169 ted with the individual end points of MI and ischemic stroke in the overall population, including in

170 DL-P was consistently associated with MI and ischemic stroke in the overall population.

171 Thrombolysis for acute ischemic stroke in the unwitnessed or extended therapeut

172 o of 4.35 ([95% CI, 1.85-10.0] P=0.0011) for ischemic stroke in the validation cohort.

173 regulates tissue damage and outcomes during ischemic stroke in vivo.

174 dose in patients with large vessel occlusion ischemic stroke in whom endovascular thrombectomy is pla

175 holesterol, and triglycerides in relation to ischemic stroke, in particular large artery and small ve

176 diseases ranging broadly from hemorrhages to ischemic strokes, in order to encourage further developm

177 son-years; HR, 1.37 [95% CI, 0.88-2.13]) and ischemic stroke (incidence rate, 5.6 versus 3.2 per 1000

178 Secondary prevention of ischemic stroke includes additional carotid surgery or s

179 Primary prevention of ischemic stroke includes lifestyle modification and diet

180 DL cholesterol exerts a protective effect on ischemic stroke independent of apoA-I needs further inve

181 eurological and motor functions, and reduced ischemic stroke infarct volume after cerebral ischemia-r

182 with smaller mitochondria are sensitized to ischemic stroke injury.

183 d Health Problems, Tenth Revision, codes for ischemic stroke, intracerebral hemorrhage, and stroke no

184 14 to December 2016, we compared the risk of ischemic stroke, intracranial hemorrhage (ICH), hospital

185 ological complications, defined as seizures, ischemic stroke, intracranial hemorrhage, or brain death

186 Ischemic stroke is a devastating complication affecting

187 Ischemic stroke is a leading cause of morbidity and mort

188 Acute ischemic stroke is a severe and life-threatening disease

189 tissue plasminogen activator (tPA) in acute ischemic stroke is associated with reduced mortality by

190 Hyperglycemia during acute ischemic stroke is common and is associated with worse o

191 A specific cohort of suspected acute ischemic stroke is employed and it is found that 99.0% p

192 Appropriate treatment of ischemic stroke is essential in the reduction of mortali

193 Ischemic stroke is responsible for a large number of neu

194 Endovascular thrombectomy (ET) for acute ischemic stroke is the current standard of care.

195 Acute ischemic stroke is the leading cause of disability and a

196 f intravenous thrombolytic therapy for acute ischemic stroke is time dependent.

197 d haemorrhage but the incidence of ALI after ischemic stroke is unclear.

198 sks of incident major coronary events (MCE), ischemic stroke (IS) and intracerebral hemorrhage (ICH)

199 Several studies have reported a high risk of ischemic stroke (IS) during the acute phase of infective

200 Early discrimination of patients with ischemic stroke (IS) from stroke mimics (SMs) poses a di

201 -term risk of myocardial infarction (MI) and ischemic stroke (IS) remains controversial.

202 tcomes including myocardial infarction (MI), ischemic stroke (IS), and peripheral artery disease (PAD

203 ides were associated with higher risk of any ischemic stroke, large artery stroke, and small vessel s

204 significantly positively associated with any ischemic stroke, large artery stroke, and small vessel s

205 bustly associated with increased risk of any ischemic stroke, large artery stroke, and small vessel s

206 tality and hepatic decompensation as well as ischemic stroke, major adverse cardiovascular events, sp

207 We applied this framework to an acute ischemic stroke microsimulation model to calculate the d

208 xamine the neuroprotective effects of RIC in ischemic stroke model.

209 primary efficacy outcome was a composite of ischemic stroke, myocardial infarction, or ischemic vasc

210 d outside of the Remote Evaluation for Acute Ischemic Stroke network: tPA (tissue-type plasminogen ac

211 In the cortex, after ischemic stroke, NFIA is required for the production of

212 th a mild-to-moderate acute noncardioembolic ischemic stroke (NIHSS score <=5) or TIA who were not un

213 ral population was 5.1 (95% CI, 4.7-5.4) for ischemic stroke (observed mortality rate 12.0/1000 perso

214 Ischemic stroke occurred in 276 patients (5.0%) in the t

215 and 1.06; and 0.64, 1.75, respectively) and ischemic stroke (odds ratio = 1.74; 95% confidence inter

216 ed with a lower adjusted odds of in-hospital ischemic stroke (odds ratio, 0.38; 95% CI, 0.24-0.59; P<

217 prescribed apixaban had a lower rate of both ischemic stroke or systemic embolism and bleeding compar

218 The incidence rate of ischemic stroke or systemic embolism was 6.6 per 1000 pe

219 ary effectiveness outcome was a composite of ischemic stroke or systemic embolism.

220 a statistically significantly higher risk of ischemic stroke or TIA (incidence rate, 18.9 vs 10.0 per

221 luated consecutive patients with cryptogenic ischemic stroke or TIA admitted in a comprehensive strok

222 tcome was a composite of the first recurrent ischemic stroke or TIA after PFO closure.

223 y for a year in 150 patients with a sentinel ischemic stroke or TIA event in the prior 6 months.

224 ticoagulation initiation after a cryptogenic ischemic stroke or TIA.

225 grelor and aspirin or aspirin alone in acute ischemic stroke or TIA.

226 The primary outcome was ischemic stroke or transient ischemic attack (TIA).

227 ogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA).

228 ion of stroke recurrence after a cryptogenic ischemic stroke or transient ischemic attack (TIA).

229 vessel wall MRI at 7 T in participants with ischemic stroke or transient ischemic attack (TIA).

230 ns at 7-T MRI in individuals evaluated after ischemic stroke or transient ischemic attack.

231 cular events in patients who have had recent ischemic stroke or transient ischemic attack.

232 .4 years (IQR, 1.4-9.2 years), there were 71 ischemic strokes or TIAs, 266 subsequent documented AF e

233 h SARS-CoV-2 infection had increased odds of ischemic stroke (OR = 3.58, 95% CI = 1.43-8.92, I(2) = 4

234 of a vascular cause, myocardial infarction, ischemic stroke, or cardiovascular death.

235 for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes tha

236 for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes.

237 mortality, hospitalization for recurrent MI, ischemic stroke, or heart failure over the subsequent 5

238 composite outcome of myocardial infarction, ischemic stroke, or hemorrhagic stroke over a period of

239 tal myocardial infarction, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina-

240 sease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina.

241 neous (nonprocedural) myocardial infarction, ischemic stroke, or ischemia-driven coronary revasculari

242 mposite of death from cardiovascular causes, ischemic stroke, or myocardial infarction (secondary com

243 mposite of death from cardiovascular causes, ischemic stroke, or myocardial infarction (secondary com

244 sease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitaliz

245 eath of CAD, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitaliz

246 For tPA payments in acute ischemic stroke, our model-based results suggest financi

247 the 5 trials, a total of 960 subjects had an ischemic stroke over a median follow-up period of 2.5 ye

248 pendently associated with increased risk for ischemic stroke (P trend=0.009).

249 se mortality of intracerebral hemorrhage and ischemic stroke patients admitted to the ICU and compari

250 odel to FM-UE measurements of 412 first-ever ischemic stroke patients and cross-validated endpoint pr

251 Acute ischemic stroke patients are at risk of acute kidney inj

252 I = 0.35-1.74, I(2) = 0%) among hospitalized ischemic stroke patients during the COVID-19 pandemic.

253 erformed a prespecified post hoc analysis of ischemic stroke patients screened for DWI-fluid-attenuat

254 urrence rate of acute kidney injury in acute ischemic stroke patients was low and was not higher in p

255 We prospectively observed 151 consecutive ischemic stroke patients with embolic large vessel occlu

256 type plasminogen activator; IV tPA) in acute ischemic stroke patients with prior ischemic stroke with

257 ESUS involves approximately 17% of all ischemic stroke patients, and these patients are typical

258 associated with acute kidney injury in acute ischemic stroke patients.

259 he risk of death within 3 months among acute ischemic stroke patients.

260 orming mechanical thrombectomy (MT) in acute ischemic stroke patients.

261 We found that following ischemic stroke, polymersomes encapsulating carnosine ex

262 am, known as the Remote Evaluation for Acute Ischemic Stroke program, has been implemented in Georgia

263 served effect of WHR was mediated by SBP for ischemic stroke (proportion mediated: 12%, 95% CI = 4-20

264 Ischemic strokes related to atrial fibrillation are high

265 with edoxaban versus warfarin were seen for ischemic stroke-related hospitalizations in vitamin K an

266 The underlying etiology of ischemic stroke remains unknown in up to 30% of patients

267 , 0.98-1.36) and 1.24 (95% CI 1.05-1.45) for ischemic stroke, respectively.

268 in animal models of congenital deafness and ischemic stroke, revealing that vascular plasticity and

269 s was the only PWI associated with increased ischemic stroke risk (hazard ratio, 1.84; 95% CI, 1.33-2

270 ations were associated with step-wise higher ischemic stroke risk in the Copenhagen General Populatio

271 ally determined gamma' fibrinogen on VTE and ischemic stroke risk.

272 artery disease risk and plasma VWF levels on ischemic stroke risk.

273 ents to the diagnosis and prognosis of acute ischemic stroke, septic shock, lung injuries, insulin re

274 oform, gamma' fibrinogen, on risk of VTE and ischemic stroke subtypes using summary statistics from g

275 derived and validated a prediction model for ischemic stroke/systemic embolism and major bleeding in

276 ted with hypothetical therapeutic agents for ischemic stroke that target the identified biomarkers.

277 patients aged older than 49 years with acute ischemic stroke that was restricted to the territory of

278 ents with atrial fibrillation (AF) and acute ischemic stroke, the association of prior anticoagulatio

279 in wild-type mice conferred protection from ischemic stroke to a similar degree as observed in mice

280 Compared with tPA-treated true ischemic strokes, tPA-treated mimics were younger (media

281 ent in many neurological disorders including ischemic stroke, trauma, and chronic neurodegenerative d

282 n patients (group A) with acute and subacute ischemic stroke underwent perfusion-weighted (PW)/diffus

283 l the age- and sex-adjusted hazard ratio for ischemic stroke was 1.20 (95% CI: 1.13 to 1.28), while t

284 the multivariable-adjusted hazard ratio for ischemic stroke was 1.60 (95% confidence interval [CI]:1

285 The highest absolute 10-year risk of ischemic stroke was 17% in active smoking individuals >7

286 Nevertheless, the association with ischemic stroke was maintained among the subgroup of mal

287 gle-nucleotide polymorphisms associated with ischemic stroke was used to calculate a GRS in each pati

288 for 5 established and 2 novel biomarkers for ischemic stroke were identified.

289 4D CT angiography for the suspicion of acute ischemic stroke were retrospectively identified.

290 (cardiovascular mortality, reinfarction, or ischemic stroke) were examined.

291 ever, overlap exists between hemorrhagic and ischemic stroke, which may reflect shared pathobiology p

292 50 mg/dL if did not have diabetes) and acute ischemic stroke who were enrolled within 12 hours from s

293 g patients aged 65 years or older with acute ischemic stroke who were treated with tissue plasminogen

294 cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebra

295 65 years or older who were treated for acute ischemic stroke with intravenous tPA within 4.5 hours fr

296 Individuals with acute ischemic stroke with ipsilateral carotid stenosis of >=5

297 In acute ischemic stroke with unknown time of onset, magnetic res

298 ad a mild-to-moderate acute noncardioembolic ischemic stroke, with a National Institutes of Health St

299 patients treated with IV tPA who had a prior ischemic stroke within 3 months and 30 655 with no histo

300 in acute ischemic stroke patients with prior ischemic stroke within 3 months.